| P50 | author | Gianluca Bossi | Q47504162 |
| P2093 | author name string | Ada Sacchi | |
| P2860 | cites work | Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model | Q72198415 |
| | Pharmacological rescue of mutant p53 conformation and function | Q73316566 |
| | Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain | Q73400021 |
| | A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy | Q74117541 |
| | The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure | Q74244104 |
| | Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53 | Q74247134 |
| | A fly with an ointment: Bcl-2 as an anti-mutator in tumors | Q74664785 |
| | Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy | Q77932308 |
| | Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells | Q78353663 |
| | CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73 | Q80445776 |
| | A novel cofactor for p300 that regulates the p53 response | Q22010639 |
| | Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway | Q23924042 |
| | p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53 | Q24290402 |
| | PUMA, a novel proapoptotic gene, is induced by p53 | Q24291463 |
| | ASPP proteins specifically stimulate the apoptotic function of p53 | Q24291844 |
| | p53 has a direct apoptogenic role at the mitochondria | Q24298888 |
| | ASPP1 and ASPP2: common activators of p53 family members | Q24305256 |
| | Identification of a novel p53 functional domain that is necessary for efficient growth suppression | Q24311276 |
| | Mdm2 promotes the rapid degradation of p53 | Q24322597 |
| | A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants | Q24530763 |
| | NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription | Q24600573 |
| | Activation of p53 in cervical carcinoma cells by small molecules. | Q24644964 |
| | In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 |
| | Regulation of p53 stability by Mdm2 | Q27860744 |
| | Control of apoptosis by p53. | Q35603381 |
| | Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses | Q35610303 |
| | Modified adenoviruses for cancer gene therapy | Q35762507 |
| | Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms | Q36047909 |
| | Chemosensitization by antisense oligonucleotides targeting MDM2. | Q36047918 |
| | Phase I trial of elactocin | Q36135821 |
| | Higher order chromosome structure is affected by cold-sensitive mutations in a Schizosaccharomyces pombe gene crm1+ which encodes a 115-kD protein preferentially localized in the nucleus and its periphery | Q36220366 |
| | Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. | Q36438353 |
| | Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression | Q36551292 |
| | Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide | Q37088668 |
| | Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts | Q37230210 |
| | Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. | Q37402942 |
| | Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants | Q40011883 |
| | The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors | Q40410023 |
| | Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells | Q40410781 |
| | Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. | Q40439787 |
| | The transcriptional repressor hDaxx potentiates p53-dependent apoptosis | Q40520539 |
| | Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. | Q40528526 |
| | The codon 72 polymorphic variants of p53 have markedly different apoptotic potential | Q40672888 |
| | Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line | Q40675789 |
| | PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy | Q40765673 |
| | Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy | Q40774297 |
| | Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling | Q40878328 |
| | Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. | Q40911261 |
| | p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes | Q41454039 |
| | Presence of a potent transcription activating sequence in the p53 protein | Q41724404 |
| | Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene | Q43624125 |
| | Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. | Q43677077 |
| | The IARC TP53 database: new online mutation analysis and recommendations to users | Q43714274 |
| | Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. | Q43955939 |
| | Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. | Q44266870 |
| | Rescue of mutant p53 transcription function by ellipticine | Q44526163 |
| | China approves first gene therapy | Q44580430 |
| | Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms | Q44748720 |
| | Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). | Q45180301 |
| | The MDM2 RING-finger domain is required to promote p53 nuclear export | Q45301160 |
| | A novel form of Epstein-Barr virus latency in normal B cells in vivo | Q45789413 |
| | The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis | Q45869930 |
| | Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy | Q45871670 |
| | Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging. | Q45885615 |
| | ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents | Q46343726 |
| | Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". | Q47245502 |
| | Promoter-specific p53-dependent histone acetylation following DNA damage | Q47984119 |
| | Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. | Q52247619 |
| | Apaf-1 is a transcriptional target for E2F and p53 | Q57274134 |
| | Kinetic Instability of p53 Core Domain Mutants | Q58322007 |
| | p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells | Q71618789 |
| | Surfing the p53 network | Q28032484 |
| | Functions of the MDM2 oncoprotein | Q28138115 |
| | The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract | Q28141340 |
| | Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis | Q28144256 |
| | BID regulation by p53 contributes to chemosensitivity | Q28211208 |
| | Mutations in the p53 gene occur in diverse human tumour types | Q28249770 |
| | KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene | Q28250929 |
| | The p53-mdm-2 autoregulatory feedback loop | Q28609811 |
| | Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 |
| | T antigen is bound to a host protein in SY40-transformed cells | Q29618321 |
| | Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 |
| | Rescuing the function of mutant p53. | Q30329984 |
| | Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 |
| | Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. | Q31810286 |
| | Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. | Q33209208 |
| | A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 |
| | Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function | Q33786826 |
| | Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis | Q33916603 |
| | Apoptotic threshold is lowered by p53 transactivation of caspase-6 | Q34035849 |
| | Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. | Q34108288 |
| | Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors | Q34379259 |
| | An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 |
| | The p53 proto-oncogene can act as a suppressor of transformation | Q34440370 |
| | Proteasome inhibition: a novel approach to cancer therapy | Q34583900 |
| | Hsp90 inhibitors as novel cancer chemotherapeutic agents | Q34583912 |
| | The MDM2 gene amplification database | Q34672224 |
| | Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. | Q34740058 |
| | Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells | Q35010309 |
| | The p53-Mdm2 module and the ubiquitin system. | Q35036580 |
| | Inhibiting the p53-MDM2 interaction: an important target for cancer therapy | Q35058579 |
| | Drug discovery and p53. | Q35101871 |
| | Decision making by p53: life, death and cancer | Q35116663 |
| | Why did p53 gene therapy fail in ovarian cancer? | Q35172779 |
| | Small molecules that reactivate mutant p53. | Q35204556 |
| | Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. | Q35207550 |
| P433 | issue | 3 | |
| P304 | page(s) | 272-284 | |
| P577 | publication date | 2007-03-01 | |
| P1433 | published in | Head & Neck | Q13703062 |
| P1476 | title | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy | |
| P478 | volume | 29 | |